Nervous System News and Research

Latest Nervous System News and Research

Last patient in EU Diamyd Phase III clinical study completes 15-month visit for type 1 diabetes

The last patient in the EU Diamyd Phase III clinical study has completed the 15-month visit, meaning that all patients in this study have completed the main 15 month study period in this trial. This important achievement in the Diamyd® Phase III program will now be followed by an intense period where the data will be compiled from the more than 60 clinics throughout Europe and from the central laboratory.

14 Feb 2011

Men and women who eat berries may have lower risk of developing Parkinson's disease

New research shows men and women who regularly eat berries may have a lower risk of developing Parkinson's disease, while men may also further lower their risk by regularly eating apples, oranges and other sources rich in dietary components called flavonoids.

13 Feb 2011

UFRF files lawsuit against Diamyd Medical

The University of Florida Research Foundation Inc. (UFRF) has filed a lawsuit in United States federal district court in Florida against Diamyd Medical claiming that UFRF is entitled to a percentage of the license fee paid to Diamyd Medical by Ortho-McNeil-Jansen Pharmaceuticals, Inc. (OMJPI).

11 Feb 2011

Athersys' MultiStem cell therapy provides multiple benefits in preclinical models of ischemic stroke

Medical researchers from The University of Texas Health Science Center at Houston (UTHealth) presented new research results at the American Heart Association International Stroke Conference that demonstrated how MultiStem-, a novel stem cell therapy being developed by Athersys, Inc. provided multiple benefits when administered in preclinical models of ischemic stroke.

11 Feb 2011

Seven-year study demonstrates clear benefits of fetal surgery to treat spina bifida in babies

Results of a landmark, seven-year National Institutes of Health-funded trial, Management of Myelomeningocele Study (MOMS), demonstrate clear benefit for babies who undergo fetal surgery to treat spina bifida, the most common birth defect in the central nervous system.

11 Feb 2011

Neuralstem updates progress of ongoing clinical trial of spinal cord stem cells in treatment of ALS

Neuralstem, Inc. updated the progress of its ongoing Phase I human clinical trial of the company's spinal cord stem cells in the treatment of ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease) at Emory University in Atlanta, Georgia.

11 Feb 2011

Zogenix completes enrollment in ZX002 Phase 3 study in opioid-experienced adults with moderate to severe pain

Zogenix, Inc. announced today the completion of enrollment in its pivotal Phase 3 efficacy study (Study 801) of ZX002. ZX002 is a novel, oral, single-entity, controlled-release formulation of hydrocodone for the treatment of moderate to severe pain in patients requiring around-the-clock opioid therapy for an extended period of time.

10 Feb 2011

Diamyd's NP2 Enkephalin Phase II study in cancer pain posted on ClinicalTrials.gov

Diamyd Medical´s US Phase II clinical trial, evaluating the ability of the candidate drug NP2 Enkephalin to reduce cancer pain, is posted on the ClinicalTrials.gov website.

10 Feb 2011

Human-worm connection research provides insight into brain development, diseases

"Man is but a worm" was the title of a famous caricature of Darwin's ideas in Victorian England. Now, 120 years later, a molecular analysis of mysterious marine creatures unexpectedly reveals our cousins as worms, indeed.

10 Feb 2011

FDA grants Neuralstem orphan drug designation for treatment of ALS with spinal cord stem cells

Neuralstem, Inc. announced that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted it orphan drug designation for the treatment of Amyotrophic Lateral Sclerosis (ALS) with its human spinal cord derived neural stem cells (NSI-566RSC), currently in a Phase I safety study to evaluate the safety of the product and the surgical route of administration in a wide range of ALS patients.

10 Feb 2011

New study: Fetal surgery for spina bifida greatly improves child's mobility

Performing delicate surgery in the womb, months before birth, can substantially improve outcomes for children with a common, disabling birth defect of the spine. Experts at The Children's Hospital of Philadelphia co-led a new landmark study showing that fetal surgery for spina bifida greatly reduces the need to divert fluid from the brain, improves mobility and improves the chances that a child will be able to walk independently.

9 Feb 2011

People with memory problems may face high risk of stroke

People who have memory problems or other declines in their mental abilities may be at higher risk for stroke, according to a study released today that will be presented at the American Academy of Neurology's 63rd Annual Meeting in Honolulu April 9 to April 16, 2011.

9 Feb 2011

Targacept initiates TC-6987 Phase 2 study in patients with asthma, Type 2 diabetes

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced the initiation of separate Phase 2 clinical studies of its product candidate TC-6987 in disorders characterized by inflammation, one in asthma and one in Type 2 diabetes.

9 Feb 2011

Zogenix receives 2011 DDP Industry Achievement Award for SUMAVEL DosePro

Zogenix, Inc. today announced that it has received the 2011 Drug Delivery Partnerships™ ("DDP") Innovation Award in the Industry Achievement category for SUMAVEL DosePro (sumatriptan injection) Needle-free Delivery System.

9 Feb 2011

CeNeRx announces FDA approval of CXB909 IND for neuroprotection and neurodegenerative disorders

CeNeRx BioPharma, Inc., a clinical-stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), today announced FDA approval of its IND and reported the first clinical results in humans for CXB909, a novel agent that has demonstrated utility in preclinical models of neuroprotection and neurodegenerative disorders.

9 Feb 2011

Life Sciences Discovery Fund announces nearly $600,000 in awards

The Life Sciences Discovery Fund (LSDF) today announced nearly $600,000 in awards to support commercial development of technologies to improve the diagnosis and management of major health conditions.

9 Feb 2011

Lundbeck announces second annual campaign to raise awareness on rare diseases

Today, Lundbeck announced its second annual Raise Your Hand to Fight Rare Diseases campaign in support of Rare Disease Day, a worldwide observance each year on February 28 to raise awareness of rare diseases.

8 Feb 2011

Single molecule FRET techniques combined with wavelet transforms give new view of AMPA receptor

A digital signal processing technique long used by statisticians to analyze data is helping Houston scientists understand the roots of memory and learning, Alzheimer's and Parkinson's diseases and stroke.

8 Feb 2011

PDL, UCB enter definitive settlement agreement to resolve all legal patent disputes

UCB SA, on behalf of its affiliate UCB Pharma S.A., and PDL BioPharma, today jointly announced that the companies have entered into a definitive settlement agreement that resolves all legal disputes between them, including those relating to UCB's pegylated humanized antibody fragment, Cimzia, and PDL's patents known as the Queen et al. patents.

8 Feb 2011

Genentech's OCEANS Phase III study of Avastin in platinum-sensitive ovarian cancer meets primary endpoint

Genentech, a member of the Roche Group, announced today that OCEANS, a Phase III study evaluating Avastin® (bevacizumab) in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of Avastin alone until disease progression in women with previously treated (recurrent), platinum-sensitive ovarian cancer, met its primary endpoint.

8 Feb 2011

Nervous System News and Research

Latest Nervous System News and Research

Last patient in EU Diamyd Phase III clinical study completes 15-month visit for type 1 diabetes

Men and women who eat berries may have lower risk of developing Parkinson's disease

UFRF files lawsuit against Diamyd Medical

Athersys' MultiStem cell therapy provides multiple benefits in preclinical models of ischemic stroke

Seven-year study demonstrates clear benefits of fetal surgery to treat spina bifida in babies

Neuralstem updates progress of ongoing clinical trial of spinal cord stem cells in treatment of ALS

Zogenix completes enrollment in ZX002 Phase 3 study in opioid-experienced adults with moderate to severe pain

Diamyd's NP2 Enkephalin Phase II study in cancer pain posted on ClinicalTrials.gov

Human-worm connection research provides insight into brain development, diseases

FDA grants Neuralstem orphan drug designation for treatment of ALS with spinal cord stem cells

New study: Fetal surgery for spina bifida greatly improves child's mobility

People with memory problems may face high risk of stroke

Targacept initiates TC-6987 Phase 2 study in patients with asthma, Type 2 diabetes

Zogenix receives 2011 DDP Industry Achievement Award for SUMAVEL DosePro

CeNeRx announces FDA approval of CXB909 IND for neuroprotection and neurodegenerative disorders

Life Sciences Discovery Fund announces nearly $600,000 in awards

Lundbeck announces second annual campaign to raise awareness on rare diseases

Single molecule FRET techniques combined with wavelet transforms give new view of AMPA receptor

PDL, UCB enter definitive settlement agreement to resolve all legal patent disputes

Genentech's OCEANS Phase III study of Avastin in platinum-sensitive ovarian cancer meets primary endpoint

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Nervous System News and Research

Latest Nervous System News and Research

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in